Key data includes ASCO oral presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA
/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its investigator sponsors will present four new abstracts at the virtual.